Filtered By:
Specialty: Cardiology
Condition: Cholesterol
This page shows you your search results in order of date.
Order by Relevance | Date
Total 101 results found since Jan 2013.
Musashi-2 binds with Fbxo6 to induce Rnaset2 ubiquitination and chemokine signaling pathway during vascular smooth muscle cell phenotypic switch in atherosclerosis
CONCLUSION: Our findings demonstrated that MSI2 could bind with Fbxo6 to induce Rnaset2 ubiquitination and the activation of chemokine signaling pathway during VSMC phenotypic switch in AS.PMID:37633478 | DOI:10.1016/j.cellsig.2023.110869
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Tao Zhang Shusheng Wu Rongwei Xu Shuguang Zhang Minghai Wang Jie Li Source Type: research
Reduction in LDL-C following treatment with inclisiran at 2 months in a single centre lipid clinic cohort
Background and Aims: Inclisiran is a new first in class small interfering RNA (siRNA) lipid lowering drug that has been shown to be effective in reducing low-density lipoprotein cholesterol (LDL-c) in randomised controlled trials. However, real-world data of its use is currently lacking. We aimed to analyse the early effects of this drug in a tertiary centre lipid clinic.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: P. Padam, L. Barton, S. Wilson, A. David, S. Walji, F. De Lorenzo, K. Ray, B. Jones, J. Cegla Source Type: research
Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research
High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
ConclusionIn this real-world patient population referred to German lipid clinics for elevated LDL-C levels, inclisiran demonstrated a high interindividual variability in LDL-C reductions. Further research is warranted to elucidate reasons for the interindividual variability in drug efficacy.Graphical abstract
Source: Clinical Research in Cardiology - July 9, 2023 Category: Cardiology Source Type: research
Steep LDL Cholesterol Reductions With ANGPTL3 siRNA in HoFH Steep LDL Cholesterol Reductions With ANGPTL3 siRNA in HoFH
A single injection every 3 months of a novel drug that targets the lipid metabolism enzyme ANGPTL3 resulted in substantial reductions in LDL cholesterol in patients with HoFH in the phase 2 GATEWAY trial.Medscape Medical News
Source: Medscape Cardiology Headlines - June 1, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Endothelial PHACTR1 Promotes Endothelial Activation and Atherosclerosis by Repressing PPAR γ Activity Under Disturbed Flow in Mice
CONCLUSIONS: Our results identified endothelial PHACTR1 as a novel PPARγ corepressor to promote atherosclerosis in disturbed flow regions. Endothelial PHACTR1 is a potential therapeutic target for atherosclerosis treatment.PMID:37199156 | DOI:10.1161/ATVBAHA.122.318173
Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 18, 2023 Category: Cardiology Authors: Dongyang Jiang Hao Liu Guofu Zhu Xiankai Li Linlin Fan Faxue Zhao Chong Xu Shumin Wang Yara Rose Jordan Rhen Ze Yu Yiheng Yin Yuling Gu Xiangbin Xu Edward A Fisher Junbo Ge Yawei Xu Jinjiang Pang Source Type: research
Lipoprotein(a) Lowering Medications - Another Step Forward in Atherosclerosis Management
J Cardiovasc Pharmacol. 2023 May 16. doi: 10.1097/FJC.0000000000001438. Online ahead of print.ABSTRACTASO and siRNA agents targeting Lp(a) appear to be promising treatment options for patients with elevated Lp(a) in addition to the classical therapies with statins or other cholesterol lowering drugs.PMID:37192439 | DOI:10.1097/FJC.0000000000001438
Source: Atherosclerosis - May 16, 2023 Category: Cardiology Authors: Boris B Boyanovsky Source Type: research
Excessive exogenous cholesterol activating intestinal LXR α-ABCA1/G5/G8 signaling pathway can not reverse atherosclerosis in ApoE < sup > -/- < /sup > mice
CONCLUSION: In a high-cholesterol environment, the intestine promotes the excretion of cholesterol from the cell through the LXRα-ABCA1/G5/G8 pathway, reduces the intestinal intake of a variety of exogenous cholesterol, and reduces the risk of AS.PMID:37061692 | DOI:10.1186/s12944-023-01810-6
Source: Atherosclerosis - April 15, 2023 Category: Cardiology Authors: Xichao Yu Xue Ding Han Feng Yunhui Bi Yu Li Jinjun Shan Huimin Bian Source Type: research
